Search

everythinglearnresearchcommunity

for

Search:↓

The combination treatment showed a higher response rate but no significant survival benefits.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Gefitinib can cause rare scarring hair loss.

The combination of encorafenib and binimetinib caused few skin issues.

Nilotinib can cause generalized keratosis pilaris.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Nilotinib can cause skin issues like red bumps and hair loss.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Gefitinib therapy can cause unusual hair growth on the nose.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Nilotinib may cause gray hair to return to its original color.

Erlotinib can cause hair loss as a side effect.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

A new mutation in the K6b gene caused a girl's late-appearing nail condition.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Gefitinib can cause hair loss without scarring.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

EGFR-TKIs can cause significant skin, nail, and organ side effects.